Search the Newsreel

BlackRock (CRSP holder) discloses 7.99M-share, 8.3% stake in CRISPR Therapeutics

BlackRock, Inc. has filed an amended ownership report, disclosing a beneficial ownership of 7,987,262 shares, or an 8.3% stake, in CRISPR Therapeutics AG common stock. The filing, a SCHEDULE 13G/A, indicates that BlackRock holds sole voting power over 7,841,979 shares and sole dispositive power …

CRISPR Therapeutics AG (CRSP) Cash Flow

This article provides a detailed cash flow statement for CRISPR Therapeutics AG (CRSP), covering quarterly and annual data for operating, investing, and financing activities. It includes key financial metrics like operating cash flow, net income from continuing operations, capital expenditures, and free cash flow …

CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

CRISPR Therapeutics AG (CRSP) is anticipated to exceed earnings estimates for the quarter ending June 2026, with an expected year-over-year increase in earnings and a significant rise in revenues. The company's positive Earnings ESP of +1.94% combined with a Zacks Rank #3 suggests a …

CRISPR Therapeutics AG (CRSP) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for CRISPR Therapeutics AG (CRSP), noting its current earnings forecast score and industry ranking. It presents analyst ratings, target prices, and a peer comparison, along with expected EPS and revenue figures. The consensus among analysts is a "Buy" …

CRISPR Therapeutics (CRSP) Enters Phase 1 With CTX112 In Allogeneic CAR T

CRISPR Therapeutics (CRSP) has initiated Phase 1 clinical trials for its allogeneic CAR T candidate CTX112, targeting lymphoma and autoimmune diseases. This move expands the company's focus beyond gene editing, aiming to address critical issues of cost, manufacturing complexity, and access associated with current …

CRSP|CRISPR Therapeutics AG|Price:46.540|Chg%:-0.990

CRISPR Therapeutics AG (CRSP) is a Switzerland-based gene editing company with high growth potential, though its stock performance has been weak recently. The company's valuation is considered fair, and institutional ownership is very high. Analysts have rated it as a "Buy" with a significant …

CRISPR Therapeutics AG (CRSP) Stock Sinks As Market Gains: What You Should Know

CRISPR Therapeutics AG (CRSP) saw its stock decline by 2.08% to $46.54, underperforming a market where the S&P 500 gained marginally. The company's shares have dropped 11.95% over the last month, lagging behind the Medical sector. Analysts forecast an EPS of -$1.1 and revenue …

CRISPR Therapeutics (CRSP) H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025 summary

CRISPR Therapeutics (CRSP) presented at the H.C. Wainwright 3rd Annual BioConnect Investor Conference 2025, detailing strategic partnerships, pipeline progress, and financial outlook. Key highlights include a co-development deal with Sirius Therapeutics for an siRNA platform, ongoing commercialization success of Casgevy, and promising Phase I …

CRISPR Therapeutics (CRSP) 43rd Annual J.P. Morgan Healthcare Conference 2025 summary

CRISPR Therapeutics (CRSP) presented a strategic overview and portfolio highlights at the 43rd Annual J.P. Morgan Healthcare Conference. The company is focused on developing transformative gene-based medicines across four franchises, including the approved CASGEVY therapy, multiple clinical programs, and a strong financial position. They …

Cathie Wood's $362 Million CRISPR Therapeutics Bet Isn't Just Bold -- It's Backed by a Catalyst Many Investors Are Underrating

If you're keeping an eye on gene-editing specialist CRISPR Therapeutics (NASDAQ: CRSP), you probably already know the up-and-coming biopharmaceutical outfit is a favorite of Ark Investment Management's CEO and chief stock picker, Cathie Wood. As of the latest look, the company's holding nearly $270 …

Monashee Investment Management LLC Takes Position in CRISPR Therapeutics AG $CRSP

Monashee Investment Management LLC has initiated a new position in CRISPR Therapeutics AG (NASDAQ:CRSP) during the first quarter, acquiring 50,000 shares valued at approximately $2.38 million, representing 1.3% of its portfolio. This move comes as CRISPR Therapeutics' stock has recently traded down 1.9% at …

Crispr Therapeutics AG (CRSP) Receives a Hold from Goldman Sachs

Goldman Sachs has maintained a "Hold" rating on Crispr Therapeutics AG (CRSP) with a price target of $48.00, following the company's shares closing at $46.99. Despite a "Moderate Buy" consensus from other analysts with a higher average price target, Crispr Therapeutics reported a quarterly …

CRSP: CRISPR Therapeutics AG Latest Stock Price, Analysis, News and Trading Ideas

This article provides the latest stock information for CRISPR Therapeutics AG (CRSP), including its current stock price, market capitalization, volume, and recent performance. It also lists recent news articles related to CRSP and highlights popular discussions on other stocks like HIMS and SPY.

CRISPR Therapeutics AG $CRSP Shares Sold by Amova Asset Management Americas Inc.

Amova Asset Management Americas Inc. reduced its stake in CRISPR Therapeutics AG (NASDAQ:CRSP) by 5.3% in the first quarter, selling over 104,000 shares, though CRSP remains a significant holding for the firm. Simultaneously, other institutional investors like Hollencrest Capital Management and KBC Group NV …

CRISPR Therapeutics stock trades steady as gene-editing pipeline advances after quarterly loss narro

CRISPR Therapeutics stock remained steady as the company narrowed its quarterly losses and advanced its gene-editing pipeline, primarily focusing on sickle cell disease and oncology. The company's financial performance was bolstered by collaboration revenues, which helped offset high research and development costs. Investors are …

Has CRISPR Therapeutics (CRSP) Fallen Far Enough To Look Undervalued?

CRISPR Therapeutics (CRSP) has experienced a significant 61% decline in its stock price over the past five years, prompting an evaluation of its current valuation. Despite the sharp drop, the stock is currently assessed as being in "about right" territory rather than clearly undervalued …

Do CRISPR Therapeutics' (CRSP) EPS Projections Clarify Its Gene‑Editing Commercialisation Path?

Earlier this week, CRISPR Therapeutics AG drew attention as analysts projected an earnings per share of US$1.10 loss alongside very large year-over-year revenue growth for its upcoming results. This combination of improving earnings expectations and strong sales momentum has sharpened the focus on how …

(CRSP) and the Role of Price-Sensitive Allocations

This article analyzes Crispr Therapeutics Ag (NASDAQ: CRSP), highlighting weak sentiment across all horizons which supports a short bias. It outlines an exceptional 47.4:1 risk-reward short setup targeting a 14.0% downside. The analysis also provides institutional trading strategies, including long, momentum breakout, and risk …

CRISPR Therapeutics (CRSP) Is Down 10.4% After EPS, Revenue Expectations Diverge From Valuation Concerns

CRISPR Therapeutics (CRSP) shares have dropped 10.4% as the market anticipates an earnings report showing improved EPS and significant year-over-year revenue growth. Despite these positive projections, concerns persist regarding the company's operating performance, financial health, and high valuation, leading investors to re-evaluate its position. …

CRISPR Therapeutics AG (CRSP) Declines More Than Market: Some Information for Investors

CRISPR Therapeutics AG (CRSP) experienced a decline of -1.63% in its latest trading session, underperforming the broader S&P 500. Shares have depreciated by 10.21% over the past month, trailing both the Medical sector and the S&P 500. Investors are anticipating upcoming earnings, with projected …

Is CRISPR Therapeutics (CRSP) Near Fair Value With $2.4B In Cash?

CRISPR Therapeutics (CRSP) stock, despite a 60% decline over five years, now appears to be at a fair valuation, not clearly cheap or expensive. With strong cash reserves of $2.4 billion and a growing gene editing pipeline, the company faces uncertainty regarding the commercial …

CRISPR Therapeutics AG (CRSP) Stock Dips While Market Gains: Key Facts

Investors Heavily Search CRISPR Therapeutics AG (CRSP): Here is What You Need to Know

Why Is CRISPR Therapeutics (CRSP) Down 0.7% Since Last Earnings Report?

Assessing CRISPR Therapeutics (CRSP) Valuation After Narrower Q1 2026 Loss And Pipeline Progress

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

CRISPR Therapeutics' Q1 Loss Wider Than Expected, Sales Miss Estimates

CRISPR Therapeutics AG (CRSP) Reports Q1 Loss, Lags Revenue Estimates

CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release

CRISPR Therapeutics to Report Q1 Earnings: Is a Beat in the Cards?

Is CRISPR Therapeutics' (CRSP) Casgevy Momentum Enough to Offset Steep 2025 Revenue Declines?

CRISPR Therapeutics AG (CRSP) Reports Q4 Loss, Lags Revenue Estimates

CRSP to Report Q4 Earnings: Is a Beat in Store for the Stock?

Should CRSP Stock Be in Your Portfolio Pre-Q3 Earnings?